Oruka Therapeutics (ORKA) Corporate presentation summary

Mission and pipeline

• Aims to enable freedom from chronic skin disease, focusing on psoriasis, psoriatic arthritis, and hidradenitis suppurativa.

• Pipeline includes ORKA-001 (anti-IL-23p19), ORKA-002 (anti-IL-17A/F), and ORKA-021 (combination regimen).

• Exclusive global rights to ORKA-001 (outside IBD) and ORKA-002 from Paragon Therapeutics.

Market opportunity and competitive landscape

• Psoriasis market exceeds $30B, with strong growth in moderate-to-severe cases and continued pharma investment.

• Recent launches like Bimzelx show non-incumbents can achieve significant market share with superior biologics.

• Dermatologists value both higher efficacy and extended dosing intervals, with potential for 50%+ share for annual dosing.

Product profiles and clinical data

• ORKA-001: Designed for best-in-class efficacy, 100-day half-life, annual dosing, and potential for off-treatment remission.

• Phase 1 data show high bioavailability, deep STAT3 inhibition, and safety consistent with IL-23 class.

• EVERLAST-A and EVERLAST-B Phase 2 trials to test higher efficacy, annual dosing, and off-treatment remissions, with key data in 2H 2026 and 2027.

• ORKA-002: Matches Bimzelx potency, 75-80 day half-life, and supports twice-yearly dosing; Phase 1 shows strong safety and PK.

• ORKA-021: Sequential combination of ORKA-002 and -001 aims for rapid, deep, and durable responses.